杜鲁特格拉维尔
替诺福韦-阿拉芬酰胺
埃法维伦兹
雷特格韦
体重增加
医学
埃替拉韦
病毒学
整合酶抑制剂
阿巴卡韦
逆转录酶抑制剂
重量变化
整合酶
内科学
利比韦林
核苷逆转录酶抑制剂
肿瘤科
队列
病毒载量
病毒血症
人类免疫缺陷病毒(HIV)
恩曲他滨
钴试剂
药理学
抗逆转录病毒疗法
人口
队列研究
作者
Kassem Bourgi,Aihua Bian,LaKeisha J. Boyd,Samir Kumar Gupta,Calvin J. Cohen,Jean C. Lee,Timothy R. Sterling,R D Moore,Catherine R. Lesko,Jordan E. Lake,George A. Yendewa,Michael Alan Horberg,Michael Jonah Silverberg,Frank Joseph Palella,Keri Althoff,Joseph B. Margolick,Peter F. Rebeiro,John Robert Koethe
标识
DOI:10.1093/infdis/jiag271
摘要
BACKGROUND: Weight gain is common following antiretroviral therapy (ART) initiation. Integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF) have been associated with greater weight gain, though prior analyses may have been confounded by the weight-suppressive effects of efavirenz (EFV) and tenofovir disoproxil fumarate (TDF). METHODS: Treatment-naive adults in the North American AIDS Cohort Collaboration on Research and Design initiating ART between 2007 and 2021 were analyzed. Predicted weight change was modeled using linear mixed effects models adjusted for demographic and clinical factors, and nucleoside reverse transcriptase inhibitor (NRTI) backbone, with subanalyses excluding EFV and stratifying by INSTI agent, NRTI, sex, and race. RESULTS: A total of 32 514 persons were included. At 2 years, INSTIs (4.9 kg, 95% CI: 4.6-5.2) and protease inhibitors (PIs) (4.7 kg, 95% CI: 4.4-5.1) were associated with greater mean predicted weight gain compared to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (2.7 kg, 95% CI: 2.4-2.9). Differences persisted when limiting analyses to TDF-containing regimens and excluding EFV. Among INSTIs, mean predicted weight gain was numerically highest with bictegravir (6.9 kg, 95% CI: 5.8-7.9), followed by dolutegravir (5.3 kg, 95% CI: 4.8-5.9), raltegravir (4.5 kg, 95% CI: 3.8-5.3), and elvitegravir (4.0 kg, 95% CI: 3.6-4.5). Participants receiving TAF with INSTIs gained more than those on TDF. Black females on bictegravir or dolutegravir with TAF had the highest gain at 2 years (10.0 kg, 95% CI: 7.4-12.6). CONCLUSIONS: Weight gain with non-EFV NNRTIs was lower than with PIs and INSTIs, with the greatest increases observed among Black females starting TAF with contemporary INSTIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI